Michelle Cohen
Psychiatric/Mental Health · Washington, PANPI 1124497995
Payments from drug & device makers
Across 1,391 payments — averaging $44.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$21K
- Teva Pharmaceuticals USA, Inc.$19K
- Otsuka America Pharmaceutical, Inc.$4K
- AbbVie$3K
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$2K
- plus $11K from 28 others
What the payments were for
- Consulting fees$6,90011%
- Speaking & faculty fees$21,98635%
- Travel & lodging$6,27710%
- Food & beverage$26,80143%
- Education$2680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 47 | $20,825 |
| Teva Pharmaceuticals USA, Inc. | 148 | $18,857 |
| Otsuka America Pharmaceutical, Inc. | 231 | $4,013 |
| AbbVie | 184 | $3,368 |
| Neurocrine Biosciences, Inc. | 121 | $2,190 |
| Alkermes, Inc. | 66 | $1,829 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 71 | $1,691 |
| Johnson & Johnson | 84 | $1,603 |
| Axsome Therapeutics, Inc. | 53 | $1,207 |
| Supernus Pharmaceuticals, Inc. | 92 | $990 |
| Lundbeck LLC | 56 | $868 |
| Vanda Pharmaceuticals Inc. | 6 | $683 |
| Corium, LLC | 41 | $660 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $600 |
| Ironshore Pharmaceuticals Inc. | 28 | $541 |
| Almatica Pharma LLC | 28 | $455 |
| Sunovion Pharmaceuticals Inc. | 36 | $340 |
| Novo Nordisk | 6 | $212 |
| Idorsia Pharmaceuticals US Inc | 6 | $200 |
| Astellas Pharma US Inc | 3 | $159 |
| Jazz Pharmaceuticals Inc. | 5 | $155 |
| Collegium Pharmaceutical, Inc. | 11 | $147 |
| Eisai Inc. | 8 | $143 |
| Biogen | 1 | $120 |
| Indivior Inc. | 5 | $101 |
| Neos Therapeutics, LP | 4 | $75 |
| Merck | 4 | $62 |
| Bausch Health US, LLC | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $21 |
| GSK | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,231 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 125 | $175,935 |
| VraylarCariprazine Hcl | 123 | $162,283 |
| Austedo XrDeutetrabenazine | 16 | $94,652 |
| CaplytaLumateperone Tosylate | 34 | $53,274 |
| UzedyRisperidone | 13 | $52,012 |
| TrintellixVortioxetine Hydrobromide | 97 | $50,730 |
| Abilify MaintenaAripiprazole | 18 | $48,621 |
| Invega SustennaPaliperidone Palmitate | 16 | $40,913 |
| AristadaAripiprazole Lauroxil | 15 | $40,789 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $14,841 |
| DayvigoLemborexant | 26 | $8,493 |
| Lurasidone Hcl | 44 | $7,583 |
| FetzimaLevomilnacipran Hcl | 11 | $5,188 |
| Divalproex Sodium ErDivalproex Sodium | 91 | $4,524 |
| Buspirone Hcl | 287 | $4,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $4,013 | $224,557143 claims |
| AbbVieVraylar, Fetzima | $3,368 | $167,471134 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $18,857 | $146,66329 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,691 | $53,27434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $600 | $50,73097 claims |
| Johnson & JohnsonInvega Sustenna | $1,603 | $40,91316 claims |
| Alkermes, Inc.Aristada | $1,829 | $40,78915 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,207 | $14,84114 claims |
| Eisai Inc.Dayvigo | $143 | $8,49326 claims |
| Almatica Pharma LLCSertraline Hcl | $455 | $1,819163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Washington
- Cortney SmithWashington$227K
- Kimberly GarciaAllentown$573K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
- Dylan KilmerGreenfield Township$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.